High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program-Reference-Cited by-同舟云学术

High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program

Published:2013-06-10 Issue:11 Volume:98 Page:1718-1725
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Intermesoli T.,Rambaldi A.,Rossi G.,Delaini F.,Romani C.,Pogliani E. M.,Pagani C.,Angelucci E.,Terruzzi E.,Levis A.,Cassibba V.,Mattei D.,Gianfaldoni G.,Scattolin A. M.,Di Bona E.,Oldani E.,Parolini M.,Gokbuget N.,Bassan R.

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis and Treatment of Burkitt Lymphoma in Adults: Clinical Practice Guidelines from ERN-EuroBloodNet "Recommendations Carried Out within the Framework of European Reference Network on Rare Haematological Diseases (ERN-EuroBloodNet)-Project ID No 10108571. ERN-EuroBloodNet is Partly Co-Funded by the European Union within the Framework of the Fourth EU Health Programme";2024

2. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial;The Lancet Haematology;2023-12

3. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial;Haematologica;2023-08-10

4. Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia;Clinical and Experimental Medicine;2023-01-30

5. Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis;Frontiers in Oncology;2022-12-23